Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Raymond James Financial

Equities researchers at Raymond James Financial initiated coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a report released on Thursday, MarketBeat Ratings reports. The firm set a “strong-buy” rating on the stock.

A number of other brokerages have also recently weighed in on MAZE. Wedbush lifted their target price on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Guggenheim boosted their target price on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, September 15th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics has a consensus rating of “Buy” and a consensus price target of $38.57.

Maze Therapeutics Stock Up 2.2%

Shares of MAZE traded up $0.69 during mid-day trading on Thursday, hitting $32.53. The company had a trading volume of 912,658 shares, compared to its average volume of 338,058. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $34.29. The business’s 50-day simple moving average is $27.53 and its 200-day simple moving average is $18.01. The stock has a market cap of $1.57 billion and a PE ratio of -1.56.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Maze Therapeutics during the first quarter valued at about $190,000. New York State Common Retirement Fund purchased a new position in Maze Therapeutics in the first quarter valued at about $25,000. Harvard Management Co. Inc. acquired a new stake in Maze Therapeutics during the 1st quarter valued at approximately $7,019,000. Charles Schwab Investment Management Inc. purchased a new stake in Maze Therapeutics during the 1st quarter worth approximately $796,000. Finally, TRV GP IV LLC acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at approximately $66,874,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.